Dr. Bruce Bode Looks Back and Forward at Automated Glucose Control Systems in Hospital Settings at ATTD20 Close Concerns and diaTribe covered Glytec co-founder Dr. Bruce Bode’s presentation ATTD 2020 (Advanced Technologies & Treatments for Diabetes) as he explored the past, present and future of automated glucose control systems in hospital settings Dr. Bruce Bode summarized decades of experience in …
MARCH 3, 2020 Glytec and AdventHealth Highlight the Broad Impact of Electronic Glycemic Management at HIMSS 2020 As One-Third of Patients Experience Increased Hospital Stays, Readmissions and Costs Due to Hypoglycemia and Hyperglycemia, eGMS Improves Outcomes and Quality of Care WALTHAM, MASS. (March 3, 2020) – Glytec, the only provider of insulin management software across the continuum of care, today …
AdventHealth Waterman and Sentara Virginia Beach General Hospital showcased reductions in hypoglycemia and glycemic practice variation utilizing Glytec’s comprehensive systems approach to glucose management.
In partnership with clinical leaders from AdventHealth Waterman and Sentara Virginia Beach General Hospital, Glytec presented two storyboards at the IHI National Forum revealing significant quality and safety improvements for hospitalized patients receiving insulin therapy. On average, this population represents as many as one of every three patients admitted to a general ward and one of every two patients admitted to an intensive care unit. Both hospitals credit their collaboration with Glytec, including utilization of the company’s FDA-cleared decision support platform, eGlycemic Management System® (eGMS®), as well as the company’s highly-tailored quality improvement services.
Glytec, the pioneer of digital therapeutics, has hired an expert team of clinicians to help clients drive and sustain full adoption of best practices in glycemic management.
Hospitals and health systems looking to establish brand dominance, competitive distinction and clinical excellence in diabetes care can turn to a team of experts at Glytec dedicated to helping facilitate full adoption of best practices.
Georgia’s largest health system is heightening the safety and efficacy of insulin therapy across its network of hospitals.
Known nationally for innovative care models, WellStar Health System, in partnership with Glytec, is taking proactive measures to optimize glycemic management for hospitalized patients. The not-for-profit health system is expanding use of Glytec’s patented and FDA-cleared eGlycemic Management System® (eGMS®) beyond its two largest facilities, WellStar Kennestone Hospital and WellStar Atlanta Medical Center, to an additional eight facilities in the Greater Atlanta and surrounding area.
The not-for-profit community medical center is partnering with Glytec to facilitate standardization of best practices in diabetes therapy management.
With as many as half of critical care patients either diagnosed with diabetes or at risk of hyperglycemia while hospitalized, Northeast Georgia Medical Center, in partnership with Glytec, is taking advanced measures to optimize glycemic management and ensure the safety and efficacy of insulin therapy. “Our organization is steadfastly committed to clinical excellence in diabetes care and glycemic management,” says Dr. Suhel Patel, Medical Director and Chair, Inpatient Medicine, Northeast Georgia Physicians Group. “By adopting the Glytec suite of technologies and services, our patients will receive insulin therapy that is personalized to their individual needs and carefully designed to support their recovery and transitions of care.”
Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.
Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s eGlycemic Management System® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.
The Wyoming, Michigan-based healthcare organization will partner with Glytec to provide patients an integrated model of technology-enabled glycemic management.
Known for high-quality, personalized care and award-winning services, Metro Health – University of Michigan Health is taking inpatient diabetes management to the next level. With a decades-long focus on ensuring glucose control is a top priority, the healthcare organization has selected Glytec’s eGlycemic Management System® (eGMS®) to advance the standardization of best practice. The software-as-a-medical-device eGMS® platform is both patented and FDA cleared.
A presentation at ATTD 2019 by renowned diabetologist and researcher, Dr. Bruce Bode, showcased superior clinical and financial outcomes with Glytec’s eGlycemic Management System® versus usual care across multiple studies.
In conclusion to his plenary session at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019), Dr. Bruce Bode delivered a call-to-action to an audience of his peers, espousing they do what is necessary to normalize glucose for all hospitalized patients (emphasis on ALL). He stressed that rates of hypoglycemia remain unacceptably high and use of sliding scale insulin continues to be prevalent despite abundant evidence denouncing it as unsafe and lacking efficacy. “Patients deserve better,” said Bode. With a clear focus on the solution to a decades-long problem of poor glucose control in hospitals, Bode described in detail the advantages of computerized decision support, highlighting data from multiple studies of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) that demonstrate consistently superior outcomes versus usual care, including significant reductions in hypoglycemia, 30-day readmissions and lengths of stay.
Presented at the 18th Annual Diabetes Technology Meeting, the study found that patients treated using Glytec’s solution had 73.2% less hypoglycemia and no bounce backs once transferred from a CCU to a general ward.
With a shifting reimbursement landscape and acuity on the rise for hospitalized patients, the need to minimize length of stay and increase throughput in critical care units is a priority for health systems nationwide. A study conducted by Riverside Medical Center of Kankakee, Illinois, the flagship facility of Riverside Healthcare and the area’s only Magnet® recognized institution, found that by using Glytec’s eGlycemic Management System® (eGMS®), patients admitted to critical care units were transferred to general wards .25 days sooner and there were no “bounce backs,” or returns from general wards to critical care units. The study, presented at the 18th Annual Diabetes Technology Meeting, also found that severe hypoglycemia among patients in critical care units was 73.2% lower when using eGMS®.
The 14-hospital health system implements Glytec’s insulin therapy optimization solution and achieves rapid, broad-based adoption of basal-bolus best practice.
Novant Health has successfully partnered with Glytec to achieve best practice for insulin therapy in accordance with American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) guidelines. Through a combination of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) and expert clinical change management program, Novant Health of Winston-Salem, North Carolina has now transitioned from manual, paper-based protocols for sliding-scale insulin therapy to fully integrated, computer-guided decision support for basal-bolus insulin therapy.
Nearly three dozen AHS acute care facilities are live with Glytec’s software for intravenous insulin optimization.
Adventist Health System (AHS), one of the largest faith-based health systems in the U.S., has successfully deployed the eGlycemic Management System® from Glytec. As a result, 33 AHS acute care facilities across seven states are now utilizing Glytec’s solution for intravenous insulin optimization.
Duke University Health System has selected Glytec’s eGlycemic Management System® to elevate the quality and safety of care for patients with diabetes and others who require insulin therapy.
With national statistics indicating that one of every three hospitalized patients requires insulin therapy during their stay, administering the right dose at the right time in accordance with best practices is integral to safe, effective care and speedy recovery. By implementing Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) for personalized medication optimization, Duke Regional Hospital of Durham, North Carolina is equipping its staff with a proven and highly efficient means to individualize and standardize insulin therapy. Among the key benefits of eGMS® are helping prevent hypoglycemia and hyperglycemia while also rapidly achieving and maintaining glycemic targets and reducing length of stay.
New Mexico’s only academic medical center will soon implement Glytec’s evidence-based eGlycemic Management System® for best practices in insulin therapy management.
University of New Mexico Hospital, already a distinguished leader in diabetes care, is partnering with Glytec to achieve the highest levels of quality and safety for hospitalized patients who require insulin therapy. Using Glytec’s eGlycemic Management System®, the Albuquerque-based academic medical center will not only introduce greater standardization and systemization around best practices in glycemic management, but will aim to realize the very significant goal of eliminating severe hypoglycemia.
The latest allowances from the USPTO address systems and methods specific to the dosing of subcutaneous insulin for acute and chronic care.
The United States Patent and Trademark Office (USPTO) has issued two more patent allowances for Glytec’s FDA-cleared proprietary software used by healthcare providers to guide the dosing of insulin. The allowances, which comprise a combined total of 52 claims, cite systems and methods specific to subcutaneous basal and bolus insulin. To date, Glytec has amassed an intellectual property portfolio of 18 issued or allowed patents for its eGlycemic Management System® (eGMS®) and has several dozen patents pending.
Atlanta-based Piedmont Healthcare will implement Glytec’s eGlycemic Management System® across all acute care facilities.
Standardizing and personalizing insulin therapy management for hospitalized patients is a goal Piedmont Healthcare is poised to achieve through expanded use of Glytec’s eGlycemic Management System®, or eGMS®. The not-for-profit healthcare system currently uses eGMS® at Piedmont Atlanta Hospital, Piedmont Newnan Hospital and Piedmont Athens Regional Medical Center. Based on a new agreement, Piedmont Healthcare will implement eGMS® at Piedmont Henry Hospital, Piedmont Fayette Hospital, Piedmont Newton Hospital and Piedmont Mountainside Hospital.
Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.
Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.
Glytec’s eGlycemic Management System® will ensure clinicians have ready access to evidence-based decision support for personalized insulin therapy management.
Fostering a culture of patient safety is integral to the care Chesapeake Regional Healthcare delivers, and a new partnership with Glytec will enable best practices in glycemic management across all inpatient service lines. Glytec’s eGlycemic Management System® will support the optimization of intravenous and subcutaneous insulin therapy during hospitalization, and will provide evidence-based guidance on transitions in insulin therapy from hospital to home.
According to new data from a quality improvement study, patients with diabetes experienced no diabetes-related readmissions, urgent care visits, or emergency department visits within 30 days of hospital discharge when their healthcare providers used Glytec’s eGlycemic Management System to guide insulin regimens prescribed at discharge.
Researchers at Eastern Virginia Medical School conducted the study and presented their findings earlier this month at the 17th Annual Diabetes Technology Meeting in Bethesda, Maryland.
New data presented at the 17th Annual Diabetes Technology Meeting observed no diabetes-related readmissions, urgent care visits or emergency department visits within 30 days of hospital discharge when using Glytec’s software.
A prospective quality improvement study led by Eastern Virginia Medical School and presented at the 17th Annual Diabetes Technology Meeting highlights the importance of properly managing transitions of care for patients with diabetes. The study observed that when providers used the Hospital-to-Home (H2H®) module of Glytec’s eGlycemic Management System® to guide insulin regimens prescribed at discharge, patients had no diabetes-related readmissions, urgent care visits or emergency department visits within the first 30 days.